Biogen Inc

ISIN US09062X1037 Symbol BIIB Industry Drug Manufacturers-General Sector Healthcare
Biogen Price
349.2USD 6.11%
1y Low: 223.2
1y High: 350.2
1y Low: 223.2
1y High: 350.2
Biogen Analyst Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
biogen.com
Market Cap
41.7 B USD
Dividend Yield
Performance 1y
41.61 %
PER
11.0

Biogen Stock Chart

Biogen Dividend Chart

Biogen Dividend Calendar

Year # Div. Div. Paid Div. Yield Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Biogen Performance

1 Week
1 Month
36.00 %
6 Months
52.32 %
Year to Date
53.08 %
1 Year
41.61 %
5 Years
65.58 %

Biogen Revenue, EBIT, and Income

Biogen Margins

Biogen Shares Outstanding

Useful Links

Search Twitter: $BIIB, #BIIB

Biogen Company Info

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaborations with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; Sangamo Therapeutics Inc.; ISD Immunotech; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Price to Earnings Ratio (PE Ratio): 11.0

The current Price to Earnings Ratio of Biogen is 11.0.
The PE Ratio is calcluated by dividing the current Biogen share price (349.2 USD) by the earnings per share (24.8).

Biogen Market Cap: 41.7 B USD

The current market cap of Biogen is 41.7 B USD.

Biogen Stock Price: 349.2 USD

The current stock price of Biogen is 349.2 USD.

Biogen ISIN: US09062X1037

The ISIN (International Securities Identification Number) of Biogen is US09062X1037.

Biogen Ticker Symbol: BIIB

The ticker symbol of Biogen is BIIB.

Biogen Address

The address of the Biogen HQ is 225 Binney Street, 02142 Cambridge, MA, USA.